NDAORALFOR SUSPENSION
Approved
Aug 2009
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
14
Clinical Trials (5)
Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
Started Jun 2017
202 enrolled
Hyperphosphatemia
An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients
Started Oct 2013
96 enrolled
Renal Failure Chronic
A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722
Started Apr 2013
16 enrolled
Healthy
An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
Started May 2012
101 enrolled
HyperphosphatemiaChronic Kidney Disease
Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia
Started Sep 2010
210 enrolled
HyperphosphataemiaChronic Kidney Disease
Loss of Exclusivity
LOE Date
Dec 6, 2030
57 months away
Patent Expiry
Dec 6, 2030
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 9095509 | Dec 6, 2030 | Product | — |